Clinical acute rejection within 1-year post-kidney transplant is believed to adversely influence long-term graft survival. 7 However, the long-term implications of subclinical rejection (SCR) and especially minor degrees of inflammation not qualifying as rejection are less clear.
Despite reductions in rates of clinical acute rejection, several studies
have found SCR to be widely prevalent. 8, 9 The concept of SCR was introduced by Rush and associates in the mid-1990s. 10 The diagnosis of SCR requires a protocol biopsy and has not been adopted by many transplant centers. In a recent survey through the United Network for
Organ Sharing, only 17% of US centers that responded to the survey perform protocol biopsies, although an additional 20% of centers perform biopsies for select high-risk recipients. 11 Hence the role of persistent degrees of low-grade inflammation in shaping outcomes remains unexplored.
The histological diagnosis of acute rejection has evolved since the introduction of the Banff classification in the 1990s. 12 The Banff classification has also evolved over time with reference to borderline rejection. The presence of tubulitis (at least t1) has remained a consistent requirement for the diagnosis of borderline rejection. However, the presence of interstitial inflammation is not an absolute requirement for the diagnosis of Banff Borderline rejection based on the 2005 and 2007 updates. 13 We wanted to study the impact of minor degrees of any inflammation (tubular or interstitial) on short-and intermediateterm kidney function and allograft histology in the modern era of immunosuppression. Figure 1 shows the total number of kidney transplants, exclusion of patients from the study, number of patients undergoing biopsy, study subjects, and number of patients with Subclinical Inflammation with stable kidney function with no inflammation or minor degrees of inflammation not qualifying for Banff IA or higher were selected for the study. Stable kidney function was defined as having a serum creatinine <0.3 mg/dL above the lowest outpatient creatinine.
| METHODS

| Study population
| Protocol biopsies
At our center, protocol biopsies are performed at 3-and 12-months posttransplant as an outpatient procedure. All biopsies are done under ultrasound guidance with an 18G spring-loaded biopsy needle. At least 1 core with a minimum of 7 glomeruli and 1 artery were needed to meet the adequacy requirements for the biopsy specimen. Experienced transplant pathologists interpreted all biopsies, and scores were validated by a pathologist (P.R.).
| Inclusion and exclusion criteria
Kidney transplant recipients who underwent biopsies at 3-months posttransplantation (including kidney-pancreas and liver-kidney transplants) were included in this prospective study. Those recipients who died or lost their graft within 3 months (n = 15) and those who did not undergo protocol biopsy (n = 90) were excluded from the study.
In addition, patients who had findings of subclinical rejection (n = 29) TCMR ≥ Banff 1A or subclinical antibody-mediated rejection (SC-ABMR) on protocol biopsy or clinical acute rejection (n = 34) (TCMR or ABMR) within the first 3 months were excluded. All transplants included in the study were ABO compatible and none of them underwent desensitization pretransplant.
| Study groups
Kidney transplant recipients with stable kidney function who had an allograft biopsy at 3 months demonstrating SCI or NI were included for this study. Kidney lesions were graded according to the Banff criteria. Patients were divided into 2 groups: Group I-NI with i + t = 0 (n = 71) and Group II: SCI with i + t > 0 and not meeting the criteria for Banff 1A rejection (n = 129).
| Immunosuppression protocol
Most of the patients received thymoglobulin induction for a total dose of 6 mg/kg, divided over 4 days. Four patients received Simulect alone, 2 in each group. All patients received a rapid 7-day corticosteroid taper. MMF was started on day of transplant at a dose of 1000 mg BID, and tacrolimus was started within 48-72 hours posttransplant.
Maintenance steroid of 5 mg daily was reserved for highly sensitized patients with calculated panel reactive antibodies >90%. Maintenance prednisone was also added for patients who developed clinical and subclinical TCMR ≥ Banff IA.
Tacrolimus levels were measured at frequent time points posttransplant to optimize levels of 8-12 ng/mL during the first 3 months and then 6-10 ng/mL thereafter.
| Testing for donor specific antibody (DSA)
HLA antibodies were detected by One Lambda LAB Screen single antigen bead assay using the HLA Fusion version 3.5.6. Background normalized mean fluorescent intensity (MFI) was determined for each donor-specific antibody (DSA). MFI value of >500 U was considered to be significant.
A de novo DSA was defined as MFI > 500 U, not present pretransplant and appearing after at least 6 weeks after transplant. DSA was checked at 1, 3, 6, 12, 18, and 24 months posttransplant. Pretransplant and posttransplant antibodies ≥500 MFI were considered positive.
| Ethical guidelines and privacy protection
Patient information used for this analysis was obtained from the 
| Data collection and data variables
Using electronic health records, data were collected on all patients including donor and recipient demographics as well as other transplant variables.
| Outcome measures
We evaluated the differences in the demographic and other transplant variables between patients with SCI and NI. We also evaluated the differences in kidney function using serum creatinine, estimated GFR In addition, we also assessed the actual graft loss rates in both groups.
| Follow-up
All patients were followed up for a mean period of 42.5 months (31-55 months) posttransplant.
| Analysis and statistical methods
Paired and unpaired t tests were used for comparison of means for normally distributed variables. Chi-square test and Fischer exact test were used for proportions. Binomial logistic regression for estimating odds ratio (OR) was used to identify significant risk variables. All P values were 2-tailed and a P value of <.05 was considered significant. Stata Version 14 was used for purposes of statistical analysis. 
| RESULTS
| Study population and groups
| Patient characteristics
Baseline donor and recipient demographics and transplant variables in the 2 groups are shown in Table 1 . There were no significant differences in recipient and donor age, sex, and race between the groups. T
were detected prior to the biopsy; 3 at the time of the biopsy and the remaining 7 were detected after the biopsy but during the first year posttransplant.
| Follow-up
The mean follow-up time was 42.5 months (range 31-54 months). Table 2 shows kidney function measured by serum creatinine and eGFR from 3 to 24 months posttransplant. By providing a value of 6.0 mg/dL for those with graft failure, the mean serum creatinine levels at 24-months posttransplant for the NI and SCI groups were 1.39 ± 0.45 mg/dL and 1.65 ± 0.85 mg/dL, respectively, P = .021. At last follow-up after a mean period of 42.5 months (31-54 months), serum creatinine in the NI and SCI groups was 1.46 ± 0.52 mg/dL and 1.69 ± 0.89 mg/dL, respectively (P = .027).
| Kidney allograft function
Immunosuppressive medications including the trough Tac levels at various time points are shown in Table 3 .
| Kidney allograft histology
Changes in acute inflammatory score from 3 to 12 months in both NI and SCI groups are shown in Figure 3 . At 12 months, only 22% of the SCI patients remained free of inflammation as compared to 43% in the NI group (P = .009). Details of the histological diagnosis and individual inflammatory scores are outlined in Tables S1 and S2 respectively. It is important to note that none of the patients reached the threshold for diagnosis of SC-ABMR.
The chronicity score (ci + ct + cg + cv) on kidney allograft histology was higher at 3 months in the SCI group (1. 7 ± 1.2) as opposed to those with NI (1 ± 0.9), P = .0001 and remained higher at 12 months posttransplant in patients with SCI (2.4 ± 1.35) as opposed to those with NI (1.9 ± 1.2), P = .02 (Table 4 ). In addition, we also evaluated IFTA scores (ct + ci). These scores in many ways mirrored the chronic scores, but did correlate better with biopsy findings from 3 months.
A multivariable analysis was performed utilizing various demographic and donor variables as well as the degree of sensitization and findings of 3-month biopsy. We detected that the presence of SCI at 3 months (OR 2.8; 95% CI, 1.31-5.92; P = .008) and delayed graft function (DGF) (OR 3.8; 95% CI, 1.1-13.5; P = .041) were independent significant risk factors for the presence of IFTA (ct + ci score ≥ 2) at 1-year posttransplant.
| Occurrence of subsequent clinical or subclinical rejection
During the follow-up period, 31/129 (24%) of patients with SCI had either clinical or subclinical rejection or lesser degrees of inflammation requiring steroid administration compared to 7/71 (10%) in the NI group (P = .015) (Table S4) . 
| Graft failure
During follow-up, 10/129 (7.7%) patients lost their allograft either due to death or graft loss in the SCI group as opposed to 2/71 (2.8%) in the NI group, P = .16. Details of graft loss based on the timing are outlined in Table S3 .
| DISCUSSION
The adverse impact of clinical acute TCMR on graft survival, especially when accompanied by lack of improvement in kidney function, has been well described. 6 The impact of subclinical rejection and especially SCI is less well defined. Several studies have looked at the role of subclinical rejection in shaping chronic changes in allograft histology.
14 D'Ardenne et al found that in patients who underwent sequential protocol biopsies, the development of interstitial fibrosis, tubular atrophy, and graft failure was preceded by infiltrates irrespective of allograft function. 15 Nankivell et al studied 120 combined kidney and pancreas patients over 10 years on maintenance immunosuppression with azathioprine, cyclosporine, and prednisone. They found that patients with persistent SCR had lower GFR at the end of 2 years. 16 Loupy et al, in their follow-up of >8 years, found that patients with early subclinical T cell-mediated rejection did well in the long run, but all of these patients were treated with steroids for their subclinical rejection. 17 However, in the era of current immunosuppression, the role of SCR and especially that of minor allograft inflammation, including inflammation in scarred areas, remains unclear. Seron et al found no difference in serum creatinine at 1 and 2 years posttransplant between patients (n = 98) with normal histology and borderline changes at protocol biopsies performed at around 3 months. 18 In contrast,
Espinoza et al found a higher serum creatinine and greater decline in GFR at 2 years in subjects who had borderline changes in protocol biopsies done at 1 year. 19 Some other studies have also shown similar findings.
8,20
Our study looked at changes of SCI, which included patients with borderline rejection as well as changes of interstitial inflammation alone in the absence of tubulitis. There is a paucity of studies that have looked into this. Heilman et al found worse outcomes at 2 years in patients with SCI, but they excluded patients who had preexisting DSAs.
21
The strengths of our study include a prospective follow-up of a large cohort of patients undergoing protocol 3-month and 1-year allograft biopsies, with meticulous longitudinal follow-up of kidney Our study demonstrated that higher inflammatory scores in patients with SCI at 3 months was associated with higher inflammatory scores at 12 months posttransplant as well as higher chronicity scores at both time points. Twenty-four percent of the SCI group developed inflammatory changes necessitating the use of additional steroid pulses within 12 months after transplantation in comparison to 10% of the NI group. The higher chronicity scores on the 1-year biopsy (chronic scores as well as IFTA scores) in the SCI group are not surprising. However, the chronicity scores in the SCI group were also higher than those in the NI group at 3 months. It is unclear whether these changes were present at the time of transplantation, since we do not have donor biopsies on the full cohort. Additionally, some progression of chronic changes was noted in the NI group as well, the reason for which is not entirely clear, other than possible differences in biopsy sampling. Our study did find that both SCI and DGF were independent risk factors for the development of IFTA at 1 year. Hence, it is possible that DGF may be contributing to some of the increase in chronicity in the NI group.
The tacrolimus levels, as well as MPA and prednisone doses, measured at several time points were similar in both groups (Table 3 ).
Our study also found an association between early SCI and development of de novo DSA, which is consistent with a recently published study by Garcia-Carro et al. 22 Whether early allograft inflammation triggers DSA formation and progression of chronicity remains to be systematically studied, although it has been suggested in the study by Garcia-Carro et al as well as others. 23 Recent studies suggest an important association between the development of de novo DSA (as opposed to memory DSA) and graft loss. 24 The long-term impact of de novo DSA formation with T cell rejection, both clinical and subclinical, in our cohort of patients remains to be evaluated.
We acknowledge several limitations to our study. Donor biopsies to ascertain whether chronic changes were donor derived and present at the time of surgery were available for only 15% of our study subjects (data not shown). However, we note that Kidney Donor Profile Index scores were similar in both SCI and NI groups, and no significant differences in the chronicity scores or IFTA scores at time 0 between SCI and NI subjects were noted in the subset of patients for which baseline donor biopsy data were available. In addition, 25% of patients at our center did not undergo protocol biopsies due to relative contraindications. However, the most common reason for exclusion, use of chronic anticoagulant or antiplatelet agents, was nonimmunologic and would not be expected to significantly affect the results of our study.
In addition, it is possible that a steroid avoidance protocol may have played a role in higher incidence of SCI.
Also, the treatment of SCI was not standardized, so no conclusions can be made with respect to the effect of treatment on the course of allograft function and progression of chronicity scores. Finally, the relatively short duration of follow-up in our study does not allow for conclusions regarding the long-term implications of SCI.
Nevertheless, we report a number of key findings in our study. We were found to be independent risk factors for higher IFTA scores at 1 year. Longer-term follow-up will be important to determine whether early biopsy findings of SCI can prognosticate long-term outcomes.
In addition, interventional studies are needed to determine whether early treatment of SCI will alter the trajectory of long-term allograft function. In conclusion, SCI occurring early after transplant does not appear to be a benign condition, and its association with factors associated with decreased long-term graft survival suggests a possible role in predicting overall long-term graft survival, in the context of rapid steroid elimination.
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